Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Leukoplakia, Oral 1Head and Neck Neoplasms 1Adenocarcinoma, Follicular 1

Interventions

Radiotherapy 26Cisplatin 17Fluorouracil 13Paclitaxel 10Carboplatin 6Chemotherapy, Adjuvant 5Cetuximab 5Immunohistochemistry 4Docetaxel 4Radiotherapy, Intensity-Modulated 3Immunoenzyme Techniques 3Hydroxyurea 3Gemcitabine 3Gefitinib 3Filgrastim 3Bortezomib 3sargramostim 2bintrafusp alfa protein, human 2aldesleukin 2Tetrahydrouridine 2SS1(dsFv)PE38 2Radiotherapy, Conformal 2Polymerase Chain Reaction 2Oxaliplatin 2Neoadjuvant Therapy 2Methotrexate 2Magnetic Resonance Spectroscopy 2Leucovorin 2Gene Expression Profiling 2Fluorodeoxyglucose F18 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Head and Neck Neoplasms × Rosiglitazone × Clear all
NCT00098852 2014-01-06

Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
25 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Head and Neck Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡